Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Post-transplant lymphoproliferative disorders.

Stephen Gottschalk1, Cliona M Rooney, Helen E Heslop

  • 1Center for Cell and Gene Therapy, Texas Children's Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA. smg@bcm.tmc.edu

Annual Review of Medicine
|January 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A reassessment of anti-CAR T-cell expansion strategies.

Blood·2026
Same author

Adoptive T-Cell Immunotherapy.

Current topics in microbiology and immunology·2026
Same author

Third-Party Viral Specific T Cells for Immunocompromised Hosts and Access Barriers: A Review and Commentary by an Expert Panel from ASTCT.

Transplantation and cellular therapy·2026
Same author

Macrophages as gatekeepers of glioma progression.

Molecular therapy. Oncology·2026
Same author

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Introduction to a review series on hemophagocytic lymphohistiocytosis.

Blood·2026

Post-transplant lymphoproliferative disorder (PTLD) is a serious complication of transplantation, often linked to Epstein-Barr virus (EBV). Advances in early detection and immunotherapy offer hope, but defining treatment indications remains challenging.

Area of Science:

  • Immunology
  • Oncology
  • Transplantation Medicine

Background:

  • Post-transplant lymphoproliferative disorder (PTLD) is a severe complication following stem cell or solid organ transplantation.
  • The majority of PTLD cases are B-cell in origin and associated with Epstein-Barr virus (EBV) infection.

Purpose of the Study:

  • To review recent advancements in understanding PTLD pathogenesis.
  • To discuss progress in early detection and novel immunotherapies for PTLD.
  • To highlight challenges in defining preemptive therapy indications and integrating new treatments.

Main Methods:

  • Review of recent literature on PTLD pathogenesis and treatment.
  • Analysis of early detection strategies, including EBV-DNA load monitoring.
  • Evaluation of novel immunotherapies such as monoclonal antibodies and T-cell therapy.

Related Experiment Videos

Main Results:

  • Improved understanding of PTLD pathogenesis has been achieved.
  • Early detection methods, like serial EBV-DNA measurement, aid in identifying high-risk patients.
  • Novel immunotherapies, including adoptive T-cell transfer, show promise.

Conclusions:

  • Significant progress has been made in PTLD management.
  • Challenges persist in determining optimal preemptive therapy guidelines.
  • Integrating novel and conventional therapies for PTLD requires further investigation.